Norprolac (Quinagolide)

Quinagolide, the active ingredient in Norprolac, is a dopamine agonist presented as an oral tablet for oral use. It is employed to treat hyperprolactinemia, prolactinoma and related infertility in adult patients. GNH USA supplies Norprolac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quinagolide acts on the dopaminergic pathway to lower excess prolactin production and is indicated for the following conditions: - Hyperprolactinemia: reduces elevated serum prolactin levels and alleviates associated symptoms. - Prolactinoma: helps shrink pituitary adenomas and normalizes prolactin secretion. - Infertility related to elevated prolactin: restores ovulatory cycles and improves fertility potential.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient tension‑type headaches. - Dizziness: occasional light‑headedness, especially on standing. - Fatigue: general tiredness or reduced energy.

Serious or Rare Side Effects: - Valvular heart disease: potential fibrotic changes in cardiac valves. - Impulse control disorders: compulsive behaviors such as gambling or shopping. - Severe hypotension: marked drop in blood pressure causing faintness. - Allergic reactions: rash, urticaria, or anaphylaxis in rare cases.

Before initiating therapy, clinicians should consider several safety measures. - Monitor prolactin levels: assess therapeutic response and adjust dose as needed. - Assess cardiac function: baseline echocardiography is advised due to valvular risk. - Evaluate psychiatric history: watch for impulse control or mood disturbances. - Avoid use in uncontrolled hypertension: risk of additive blood‑pressure lowering. - Use caution in hepatic impairment: metabolism may be reduced. - Store at below 25°C: keep in the original pack, protect from moisture.

Quinagolide may interact with other medicines, requiring attention to the following categories.

Major Interactions (Avoid): - Ergot derivatives: combined use can cause severe vasospasm. - Potent CYP3A4 inhibitors: may increase quinagolide plasma concentrations. - Other dopamine agonists: risk of excessive dopaminergic stimulation.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect, monitor blood pressure. - SSRIs: potential for serotonin syndrome when combined. - Antipsychotics: dopamine antagonism may reduce quinagolide efficacy. - Oral contraceptives: possible reduction in contraceptive effectiveness.